Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Pediatric dermatologists must play an active role in treating obesity in children, according to a presenter at the Society ...

While Ozempic is only approved to treat Type-2 diabetes by the NHS, Mounjaro and Wegovy are now approved for weight loss.